|

Blinatumomab Clinical Trials

34 actively recruiting trials across 11 locations

No change since May 2026

Also known as: 6-MP, 853426-35-4, AMG 103, AMG 103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, AMG-103 +24 more

Pipeline

Phase 1: 4Phase 2: 15Phase 3: 4Phase 1/2: 5Phase 2/3: 3

Top Sponsors

M.D. Anderson Cancer Center6
National Cancer Institute (NCI)4
Institute of Hematology & Blood Diseases Hospital, China4
St. Jude Children's Research Hospital2
First Affiliated Hospital of Zhejiang University2

Indications

Cancer33
Acute Lymphoblastic Leukemia6
Recurrent B Acute Lymphoblastic Leukemia4
B Acute Lymphoblastic Leukemia4
Refractory B Acute Lymphoblastic Leukemia3

Other13 trials

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Phase 2/3

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

N/A

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

N/A

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Phase 2

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

Phase 2/3

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Phase 2

Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Phase 2

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Phase 3

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Phase 2/3

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

N/A

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Phase 2

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Phase 3

Birmingham, Alabama6 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Alabama at Birmingham Cancer Center

Phase 2

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital of Alabama

Phase 3

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

University of Alabama at Birmingham

Phase 1

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Houston, Texas5 trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 1/2

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

MD Anderson Cancer Center

Phase 1/2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2

Chicago, Illinois2 trials

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

University of Chicago Comprehensive Cancer Center

Phase 1

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Phoenix Children's Hospital

Phase 1/2

Scottsdale, Arizona1 trial

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

HonorHealth Research and Innovation Institute

Phase 2

Duarte, California1 trial

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1

Atlanta, Georgia1 trial

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Northside Hospital

Phase 2

The Bronx, New York1 trial

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Montefiore Einstein Comprehensive Cancer Center

Phase 1/2

Tulsa, Oklahoma1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Saint Francis Children's Hospital

Phase 2

Memphis, Tennessee1 trial

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Milwaukee, Wisconsin1 trial

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Children's Hospital of Wisconsin

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.